Forest Enters Into Fifth Bystolic Settlement

January 22, 2013
Glenmark Generics can market a generic version of Forest Laboratories’ hypertension drug Bystolic — potentially as soon as Sept. 17, 2021 — under terms of the settlement of a patent infringement case between the two companies. Glenmark can launch three months before the expiration of Forest’s exclusivity on Dec. 17, 2021, or on the date Glenmark receives final approval of its ANDA — whichever is later.
Generic Line